Company
Saranas
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
2
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$13.7M
6 Form D offerings, 2012 to 2020
Equity
$12.1M
Stock sold for cash
Debt and convertible notes
$1.7M
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: debt, $1.7M raised of $2.0M sought, first sale Apr 28, 2020, 39 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- Saranas Inc.; Saranas LLC
- Headquarters
- Houston, Texas
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1615461 ↗, CIK 1548012 ↗
Executives, directors and promoters
As listed on the latest Form D.
7 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Saranas.
Latest FDA decisions
K230273 · Decided May 25, 2023 · 114 days after receipt
Device type: Intravascular Bleed Monitor (QFJ) · Cardiology
- Early Bird Bleed Monitoring SystemNew device typeDe Novo
DEN180021 · Decided Mar 1, 2019 · 312 days after receipt
Device type: Intravascular Bleed Monitor (QFJ) · Cardiology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT05077657 · 203 participants · Start Nov 29, 2021 · Primary completion Dec 19, 2023
Device: Early Bird® Bleed Monitoring System; Impella® · For: Coronary Artery Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Gary, Indiana · 11 sites in all
NCT03621202 · 66 participants · Start Aug 13, 2018 · Primary completion Jun 30, 2019
Device: Saranas Early Bird Bleed Monitoring System (EBBMS) · For: Endovascular Procedures
Sites: Gainesville, Florida; Morristown, New Jersey; New York, New York · 5 sites in all
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Early Bird Bleed Monitoring System Introducer Sheath Set, REF: FG001-01 (6F), FG001-02 (8F)Open, Classified
Z-1684-2022 · Started Aug 10, 2022
Reason given: Bleed monitoring system device design error, causing the device to not power on and complete the series of self-tests so instructions for use being updated to include device check before use ensure that the device is functioning appropriately.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Intravascular Bleed Monitor (QFJ)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.